Afterward, the daily treatment was newly modified: duloxetine, clonazepam, paracetamol and oxycodone/naloxone daily doses were halved, while THC/CBD was increased to 15 mg q8 hr. Adverse events due to the cannabinoids were never observed. For certain, CBD differs from all the other analgesic drugs considering its pharmacological target and mechanism of action. The simultaneous improvement of mood, quality of life and sleep could rather be attributed to the psychotropic properties of THC, able to induce energizing effects and whet appetite.
E D I T O R I A L

Including cannabinoids in the treatment of painful schwannomatosis
Schwannomatosis is a rare form of neurofibromatosis affecting one in approximately 40,000 individuals. It is a clinical condition represented by the development of schwannomas, benign encapsulated tumors originating from Schwann cells. Schwannomas preferentially affect the spine (74%) and peripheral nerves (89%).
The distinctive hallmark of Schwannomatosis is intractable and debilitating pain (Gonzalvo et al., 2011; Lu-Emerson & Plotkin, 2009) , reported by about two-thirds of patients (Merker, Esparza, Smith, Stemmer-Rachamimov, & Plotkin, 2012) . Pain is not strictly linked to tumor growth or mechanical nerve compression. There is growing evidence that Schwann cells contribute to pain by secreting a number of trophic and inflammatory substances including tumor necrosis factor-α (TNF-α), that sensitize nociceptors (Campana et al., 2006; Lattanzi et al., 2015; Watkins & Maier, 2003) . In addition, TNF-α leads to inflammatory pain such as neuritis (Romero-Sandoval & Eisenach, 2007) . Nerve growth factor (NGF) is also expressed by Schwann cells promoting pain and long-lasting hyperalgesia (Lewin, Ritter, & Mendell, 1993; Mills et al., 2013; Rukwied et al., 2010; Thompson, Dray, McCarson, Krause, & Urban, 1995) . It is interesting that localized hyperalgesia is attenuated by a transient receptor potential vanilloid 1 (TRPV1) antagonist, suggesting a role of this receptor (Mills et al., 2013) as a potential target of pain treatment.
We describe the medical history of a 47-year-old man with Schwannomatosis who accessed our neurology department in November 2016.
The onset in 2011 featured signs and symptoms of neuropathic pain, such as paroxysmal shooting pain in the forearms, legs, and inguinal area, together with superficial mechanical allodynia, paresthesia, and dysesthesia in the same areas. Neurologic and imaging examinations (MRI, EMG, ENG, needle biopsy) revealed multiple neurinomas of unknown cause.
The patient described his pain as ranging from a tingling or needle pricking sensation to that of a classic jolting shock or as if someone were tightly pinching a nerve, making it impossible for him to extend his limbs. to 10 mg of active substance, 3 times/daily, after increased until 15 drops equal to 15 mg, 3 times/daily for achieve a better state of well-being); duloxetine 120 mg; clonazepam drops (4,5 mg). This last treatment has been ongoing for about a year and it is still ongoing.
The patient had an overall improvement in pain scores (6/10), motor activity, quality of sleep, social relations and mood.
Progressively the fatigue was reduced and the patient could walk on his own.
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